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Abstract
Introduction: Tumor cell interactions with the microenvironment, especially those of bone-marrow-derived
myeloid cells, are important in various aspects of tumor metastasis. Myeloid-derived suppressor cells (MDSCs) have
been suggested to constitute tumor-favoring microenvironments. In this study, we elucidated a novel mechanism
by which the MDSCs can mediate spontaneous distant metastasis of breast cancer cells.
Methods: Murine breast cancer cells, 4T1 and EMT6, were orthotopically grafted into the mammary fat pads of
syngeneic BALB/c mice. CD11b+Gr-1+ MDSCs in the spleen, liver, lung and primary tumor mass were analyzed. To
evaluate the role of MDSCs in the distant metastasis, MDSCs were depleted or reconstituted in tumor-bearing
mice. To evaluate whether MDSCs in the metastasizing tumor microenvironment affect breast cancer cell behavior,
MDSCs and cancer cells were co-cultivated. To investigate the role of MDSCs in in vivo metastasis, we blocked the
interactions between MDSCs and cancer cells.
Results: Using a murine breast cancer cell model, we showed that murine breast cancer cells with high IL-6
expression recruited more MDSCs and that the metastasizing capacity of cancer cells paralleled MDSC recruitment
in tumor-bearing mice. Metastasizing, but not non-metastasizing, tumor-derived factors induced MDSCs to increase
IL-6 production and full activation of recruited MDSCs occurred in the primary tumor site and metastatic organ in
the vicinity of metastasizing cancer cells, but not in lymphoid organs. In addition, tumor-expanded MDSCs
expressed Adam-family proteases, which facilitated shedding of IL-6 receptor, thereby contributing to breast cancer
cell invasiveness and distant metastasis through IL-6 trans-signaling. The critical role of IL-6 trans-signaling was
confirmed in both the afferent and efferent pathways of metastasis.
Conclusion: In this study, we showed that metastasizing cancer cells induced higher MDSCs infiltration and
prompted them to secret exaggerated IL-6 as well as soluble IL-6Ra, which, in turn, triggered a persistent increase
of pSTAT3 in tumor cells. This potential tumor-MDSC axis involving IL-6 trans-signaling directly affected breast
cancer cell aggressiveness, leading to spontaneous metastasis.
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Introduction
Breast cancer is the leading cause of cancer-associated
death in women worldwide [1]. Despite recent improve-
ments in early detection and effective adjuvant che-
motherapies, about one-third of patients with early
disease will relapse with distant metastasis [2]. Metastasis
of breast cancer remains a largely incurable disease and
is the major cause of mortality among breast cancer
patients [3]. Cancer metastasis is a complex process com-
prising dissociation of cancer cells from the bulk tumor,
invasion of the neighboring tissue, intravasation, trans-
port through the vascular system, extravasation, engraft-
ment of disseminated cells and, finally, outgrowth of
micrometastases [4]. In our previous study, orthotopically
grafted human breast cancer cells expressing high levels
of IL-6, but not those with low levels of IL-6, sponta-
neously metastasized to the lung and liver in immuno-
compromised NOD/scid/gc-deficient (NOG) mice [5].
IL-6 signaling in cancer cells themselves imbued them
with cancer stem cell properties and epithelial-to-
mesenchymal transition (EMT) phenotypes, which facili-
tate cancer cell invasion into the surrounding tissue and
blood vessels, and cause distant metastasis [5,6]. In addi-
tion, IL-6 is known to be an important mediator of the
expansion and recruitment of myeloid-derived suppressor
cells (MDSCs) [7,8].
MDSCs are a heterogeneous population of cells com-
prising immature cells of monocyte or granulocyte line-
age. They expand dramatically under conditions such as
trauma, tumor growth and various chronic inflammatory
disorders, including infection, sepsis and immunization
[7,8]. Originally described as suppressive myeloid cells,
thus-expanded MDSCs negatively regulate immune
responses through multiple contact-dependent and
-independent pathways [8,9]. Nitrosylation of T cell
receptors (TCRs) and CD8 molecules leads to defective
cytotoxic T cell (CTL) responses, rendering the cells
unresponsive to antigen-specific stimulation [10]. Short-
age of L-arginine due to arginase I activity in MDSCs
inhibits T cell proliferation by several mechanisms [11].
Nitrous oxide (NO) and transforming growth factor-b
(TGF-b) produced by MDSCs induced further immuno-
suppressive microenvironments favoring tumor growth
[7-9]. In addition to the abovementioned immunosup-
pressive functions, MDSCs actively formulate microen-
vironments favoring the generation and survival of
cancer cells in association with chronic inflammation.
Induced expression of IL-1b in gastric epithelial cells
induces the recruitment of MDSCs and leads to gastric
inflammation and cancer, while activation of nuclear
factor-kappa B (NF-B) in MDSCs is strongly associated
with carcinogenesis [12]. MDSCs have been suggested
to facilitate cancer cell metastasis through their
immunosuppressive activities [8,13,14]. Recently, cancer-
derived remote signals were shown to induce the accu-
mulation of myeloid cells including MDSC populations
in putative metastatic sites before migrating cancer cells
arrived, forming a ‘pre-metastatic niche’, which aided
extravasation of migrating cancer cells and facilitated
new blood vessel formation [15-17]. Accumulating evi-
dence shows that tumor-derived factors and tumor-cell-
signaling mediators, such as Hsp72 and S1pr1, activate
MDSCs to potentiate their immunosuppressive func-
tions or increase the recruitment and colonization of
these cells into pre-metastatic tissues [18,19]. Increased
circulating MDSCs in breast cancer patients has been
shown to be correlated with clinical cancer stage and
metastatic tumor burden [20,21]. However, the evidence
for the direct roles of cancer cell-exposed MDSCs in
enhancing cancer cell aggressiveness, leading to sponta-
neous metastasis of these cells, from their invasion into
the surrounding tissue and vascular system to their
colonization of the target organ and the underlying
mechanisms is either missing or merely circumstantial.
We questioned whether MDSCs activated by cancer
cells directly increase breast cancer aggressiveness lead-
ing to spontaneous distant metastasis. To adequately
evaluate the mutual interaction of breast cancer cells
and inflammatory cells including MDSCs, we utilized
murine models in which breast cancer cells were ortho-
topically grafted into immunocompetent syngeneic mice
[22]. We found that murine breast cancer cells with
high IL-6 expression recruited more MDSCs and that
the metastasizing capacity of cancer cells paralleled
MDSC recruitment in tumor-bearing mice. Depletion
and addition of MDSCs from tumor-bearing mice,
respectively, reduced and increased the distant metas-
tasis of breast cancer cells. Metastasizing, but not non-
metastasizing, cancer cells activated MDSCs, increasing
their expression and secretion of both IL-6 and soluble
IL-6Ra, and facilitated breast cancer cell invasiveness
and distant metastasis through IL-6 trans-signaling, acting
both in afferent and efferent metastatic pathways. Thus,
we provide evidence that breast cancer cells and MDSCs
formed a synergistic mutual feedback loop and that
thus-potentiated MDSCs directly affect breast cancer
cell aggressiveness, leading to spontaneous metastasis.
Methods
Animals
BALB/c mice were purchased from the Jackson Labora-
tory (Bar Harbor, MA, USA). Experiments involving
mice were approved by the Institutional Animal Care
and Use Committee of Seoul National University
(authorization no. SNU05050203).
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Cell lines
The mouse breast carcinoma cell lines 4T1 (ATCC
CRL-2539) and EMT6 (ATCC CRL-2755) were pur-
chased from the American Type Culture Collection
(Manassas, VA, USA) and maintained in RPMI 1640
(WelGENE, Daegu, South Korea) supplemented with
10% heat-inactivated fetal bovine serum (FBS) (GIBCO,
Grand Island, NY, USA) and 1% antibiotics (100 U/ml
penicillin and 100 μg/ml streptomycin) at 37°C in a
humidified 5% CO2 atmosphere. IL-6-expressing EMT6
cells (EMT6_IL-6 cells) were established by transfection
with the pcDNA3.1_IL-6 construct using PromoFectin
(PromoKine, Heidelberg, Germany), according to the
manufacturer’s instructions. Control cells were transfected
with the pcDNA3.1 vector only. Stably transfected clones
were established by selection with G418 (Sigma-Aldrich,
St. Louis, MO, USA) at a concentration of 500 μg/ml
for three weeks. IL-6-expressing EMT6 (EMT6_IL-6)
clones were selected by ELISA. IL-6-knockdown 4T1
cells (4T1_shIL-6 cells) and Stat3-knockdown 4T1 cells
(4T1_shSTAT3 cells) were established using the lenti-
viral vectors containing the shRNA (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Cells were infected
with the shIL-6 or shSTAT3 virus and cultured in the
presence of puromycin, and IL-6-knockdown 4T1
(4T1_shIL-6) and Stat3-knockdown 4T1 (4T1_shStat3)
clones were selected by ELISA and Western blotting,
respectively.
Tumor models
4T1 and EMT6 cells (1×105/mouse) were injected into
the mammary fat pads of BALB/c mice. Tumor growth
was monitored every other day thereafter. At 26 or 29 days
after injection, the mice were euthanized and primary
tumor masses, livers and lungs were fixed in 4% parafor-
maldehyde (PFA) for 24 hours and embedded in para-
ffin. Sections (5 μm) were stained with H & E for
histopathological analysis. Numbers of tumor masses in
the liver and lungs were determined under a dissecting
microscope before fixing with 4% PFA. To deplete
MDSCs, mice were intraperitoneally injected with 100 μg
of anti-Gr-1 antibody (RB6-8C5, eBioscience, San Diego,
CA) or control Rat immunoglobulin G 1 (IgG1) twice a
week, starting three days after 4T1 cell injection. To
block IL-6 trans-signaling in the afferent pathways of
metastasis, 4T1 cells were injected into the mammary fat
pads and gp130-Fc (R&D Systems, Minneapolis, MN,
USA) was administered continuously using an osmotic
mini-pump (5 or 10 μg for 14 days; Alzet, Cupertino, CA,
USA). To block IL-6 trans-signaling in the efferent
pathways of metastasis, 4T1 cells were injected intrave-
nously into BALB/c mice and mice were intravenously
injected with gp130-Fc (2.5 μg/mouse) 4 four days after
cell injection.
Flow cytometry and MDSC isolation
To analyze MDSCs, mice were sacrificed 19 or 21 days
after cancer cell injection. Mononuclear cells from the
liver, lungs and primary tumor masses were isolated by
Percoll (Amersham, GE healthcare, Buckinghamshire,
UK) gradient centrifugation. Tissues were digested with
collagenase D (1 mg/ml, Invitrogen, Carlsbad, CA, USA)
and DNase I (0.5 U/ml, Sigma-Aldrich) for one hour at
37°C. Cells were suspended in 30% Percoll, layered onto
the top of a 70% Percoll gradient and centrifuged (800 × g,
20 minutes). The interface was retained. Next, the cells
were incubated with mAbs to mouse CD11b, Ly6C and
Gr-1 that were conjugated to phycoerythrin, PerCP-Cy5.5,
or allophycocyanin (eBioscience). They were then analyzed
using a FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA, USA) and FlowJo software (Tree Star, Ashland,
OR, USA). To isolate splenic MDSCs from naïve or
tumor-bearing mice, splenocytes were prepared and
labeled with phycoerythrin-conjugated anti-CD11b mAb
(BD Pharmingen, San Jose, CA, USA) and allophycocyanin-
conjugated anti-Gr-1 mAb (eBioscience). CD11b+Gr-1+
MDSCs were purified using a FACS Aria cell sorter
(BD Biosciences). The purity after sorting was greater
than 95%.
Tumor and MDSC conditioned medium preparation
EMT6 cells (1×104) and 4T1 cells (1×104) were incu-
bated for 72 hours on a 24-well plate and the culture
supernatants were collected. To obtain MDSC CM,
FACS-sorted splenic MDSCs (4×105) were cultured for
24 hours. 4T1/MDSC-CM and EMT6/MDSC-CM were
prepared by cultivating MDSCs (4×105) in 50% (v/v)
4T1-CM or EMT6-CM for 24 hours. A volume of 4T1/
MDSC-CM containing 1 ng of IL-6, or the same volume
of EMT6/MDSC-CM or MDSC-CM, was added to the
4T1 and EMT6 cell cultures. To some cultures, the
following signaling inhibitors were added; Stat3 inhibitor
peptide (1 μM; Millipore, Billerica, MA, USA), PI3K
inhibitor (LY294002, 10 μM; Calbiochem, Billerica, MA,
USA), NF-B inhibitor (Bay-117082, 10 μM; Calbio-
chem), JNK inhibitor (SP600125, 10 μM; Calbiochem),
p38 MAPK inhibitor (SB403250, 10 μM; Cell Signaling,
Danvers, MA, USA), and ERK inhibitor (PD98059, 10 μM;
Calbiochem).
Immunofluorescence microscopy
Tissues were fixed in 4% PFA and embedded in paraffin.
Sections were stained with H & E for histopathological
analysis. To investigate IL-6, IL-6Ra, and Adam17
expression levels in MDSCs, sections were stained with
anti-Gr-1 mAb and other appropriate antibodies. The
following primary antibodies were used: anti-mouse IL-6
(Abcam, Cambridge, MA, USA), anti-mouse IL-6Ra
(Santa Cruz Biotechnology, Santa Cruz, CA, USA),
Oh et al. Breast Cancer Research 2013, 15:R79
http://breast-cancer-research.com/content/15/5/R79
Page 3 of 16
anti-mouse Adam17 (Abcam) and anti-mouse Gr-1
(eBioscience). The following secondary antibodies were
used: Alexa 488-conjugated anti-rabbit IgG (Invitrogen)
and Alexa 594-conjugated anti-rat IgG (Invitrogen).
Image acquisition and processing was performing using
a confocal fluorescence microscope (Olympus, Center
Valley, PA, USA) and an FV10-ASW 2.0 Viewer
(Olympus).
ELISA
EMT6 and 4T1 cells were plated on a 24-well plate (1 ×
104/well). The cells were permitted to grow for 24 or 48
hours. Supernatants were collected and assayed for IL-6
and soluble IL-6Ra levels by ELISA. For IL-6 detection,
anti-mouse IL-6 (eBioscience) was used as the capture
antibody, biotinylated anti-mouse IL-6 (eBioscience) in
0.1% BSA in PBS/T as the detection antibody and recombi-
nant IL-6 (eBioscience) as the standard. To detect soluble
IL-6Ra, we used anti-mouse IL-6Ra (R&D Systems) as
the capture antibody, biotinylated anti-mouse IL-6Ra
(R&D Systems) as the detection antibody and recombinant
IL-6Ra (R&D Systems) as the standard.
RNA analysis
RNA was isolated from sorted splenic MDSC using the
RNeasy kit (QIAGEN; 74104, Hilden, Germany). cDNA
was generated from 1 μg of total RNA by reverse tran-
scriptase from Moloney Murine Leukemia Virus (M-MLV)
(TAKARA, Shiga, Japan), and subjected to PCR. The




ATCTC-3’. PCR products were analyzed by 1.5% agarose
gel electrophoresis.
Western blot analysis
Cells were harvested in lysis solution containing 50 mM
Tris/HCl (pH 7.6), 1% NP40, 150 mM NaCl, 2 mM
EDTA, 100 μM PMSF, a protease inhibitor cocktail
(Roche Applied Science, Basel, Switzerland), and a phos-
phatase inhibitor (Sigma-Aldrich). After incubation on ice
for 30 minutes, cellular debris was removed by centrifuga-
tion (10 minutes, 4°C). Proteins (10 μg) were separated by
SDS-PAGE and then transferred to a polyvinylidene
difluoride membrane. After blocking with 5% skim milk,
the membranes were probed with an appropriate antibody.
Blots were developed with an enhanced chemilumines-
cence Western blotting detection system (Amersham,
GE Healthcare, Buckinghamshire, UK). The following
antibodies were used: anti-b-actin (Sigma-Aldrich),
anti-phospho-Stat3 (Tyr705) (Cell Signaling, Danvers,
MA, USA), anti-Stat3 (Santa Cruz Biotechnology), anti-
I-B (Santa Cruz Biotechnology), anti-phospho-JNK
(Santa Cruz Biotechnology), anti-phospho-ERK (Santa
Cruz Biotechnology), and anti-phospho-p38 (Cell
Signaling).
Invasion assay
Matrigel matrix solution (200 μg/ml, Matrigel™ Base-
ment Membrane Matrix, BD Bioscience) was applied to
each Transwell (Falcon, Franklin Lakes, NJ, USA). 4T1
cells (5×104) were seeded into the upper chamber of the
Transwell and then the lower chamber was filled with
collagen matrix (5 μg/ml). Invasion assays were carried
out for 18 hours. Non-invading cells on top of the
matrix were removed by rubbing with a moistened cotton
swab. Invaded cells on the lower surface of the Matrigel
matrix were fixed with 4% PFA and stained with 0.2%
crystal violet. Cells were counted using ImageJ software
(version 1.46).
Statistical analyses
The two-tailed Student’s t-test was used to compare
measurements for pairs of samples. Two-way analysis of
variance (ANOVA) and Bonferroni post hoc testing were
used to compare the tumor volumes of the two groups.
The SPSS software (SPSS Inc.) was used for all statistical
analyses.
Results
Correlation of spontaneous distant metastasis of breast
cancer cells with MDSC recruitment
In our previous report, high IL-6-secreting human
breast cancer cells revealed more aggressive phenotypes
including enhanced distant metastasis [5] and recruited
more inflammatory cells (our unpublished data) com-
pared to the low IL-6 expressing cells. In another report,
we also showed that damaged epithelial cells produced
IL-6 and recruited inflammatory cells including neutro-
phils [23]. Thus, we assumed that IL-6 derived from
cancer cells could affect the metastasis of cancer cells
through inflammatory cell, including MDSC, recruit-
ment. To elucidate the relationship between MDSC
recruitment and distant metastasis of cancer cells, we
created a murine breast cancer model using 4T1 and
EMT6 breast cancer cells, which exhibit differential IL-6
expression [see Additional file 1, Figure S1]. 4T1 and
EMT6 cells were orthotopically grafted into the mam-
mary fat pads of syngeneic BALB/c mice. Primary tumor
growth was slightly but significantly greater for EMT6
cells compared to 4T1 cells during the entire experi-
mental period (Figure 1A). At 26 days after grafting, 4T1
cancer cells showed extensive lung metastasis, while
EMT6 cancer cells showed no distant metastasis in the
lung, liver, bone or brain (Figure 1B). IL-6-expressing
4T1 cell-bearing mice showed dramatic recruitment of
CD11b+Gr-1+ MDSCs in the spleen (a lymphoid organ),
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Figure 1 Metastatic cancer cells facilitate recruitment of MDSCs. (A-B) EMT6 and 4T1 cells were injected into the mammary fat pads of
BALB/c mice. (A) Primary tumor growth (n = 8). (B) Representative photographs of lungs 26 days after cell injection (H & E). (C) The
percentages and absolute numbers of MDSCs (CD11b+Gr-1+) at 19 days (n = 4). (D) 4T1 cell-bearing mice were treated intraperitoneally with
anti-Gr-1 antibodies. Primary tumor growth (n = 8). (E) Numbers of tumor nodules in the lungs from 4T1 cell-bearing mice at 26 days. MDSCs,
myeloid-derived suppressor cells.
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metastasizing organs (liver and lung) and primary tumor
mass; the total number of MDSCs recruited was two to
eight times higher in 4T1 cell-bearing mice than in
EMT6 cell-bearing mice (Figure 1C and see Additional
file 1, Figure S2). To further evaluate the role of MDSCs
in the distant metastasis, the 4T1 cell tumor-bearing
mice were depleted of MDSCs. Depletion of MDSCs
reduced 4T1 lung metastasis (P = 0.0006) and primary
tumor growth in the mammary fat pads (Figure 1D and
1E). These results show that MDSCs that expanded and
recruited in the tumor-bearing mice are critically asso-
ciated with the distant metastasis of cancer cells.
Induction of IL-6 expression facilitated MDSC recruitment
and increased their metastatic capacity
We next evaluated whether IL-6-mediated MDSC
recruitment promoted the metastasis of EMT6 cancer
cells. We stably transfected EMT6 cells with a vector
encoding murine IL-6 (EMT6_IL-6) [see Additional file 1,
Figure S3A]. EMT6_IL-6 cancer cells grafted into the
mammary fat pads of syngeneic recipients recruited more
MDSCs to the spleen, liver, lung and primary tumor
mass compared to the control empty vector-transfected
EMT6 (EMT6_Con) cells (Figure 2A). The percentages
and numbers of MDSCs recruited to these sites were
comparable in EMT6_IL-6-bearing mice and 4T1 cell-
bearing mice (Figure 1B and see Additional file 1, Figure
S3B). EMT6_IL-6 cells showed increased tumor growth
compared to the control EMT6_Con cells (Figure 2B).
However, unexpectedly, distant lung metastasis was only
slightly increased in EMT6_IL-6 cell-bearing mice
(P = 0.039) (Figure 2C). Thus, we concluded that IL-6
secreted from breast cancer cells is an important and
sufficient factor for MDSC expansion and recruitment,
but that additional factors are required to facilitate the
recruited MDSC-mediated metastasis of cancer cells.
To reconstitute a microenvironment that more closely
resembles that of 4T1 cell-bearing mice, we adoptively
transferred splenic MDSCs from 4T1 cell-bearing mice
into EMT6 cell-bearing mice. MDSC-transferred EMT6
cell-bearing mice showed reduced primary tumor
growth in the mammary fat pads, and only slightly
increased lung metastasis, compared to vehicle-treated
EMT6 cell-bearing mice (Figure 2D). Thus, neither
repeated transfer of splenic MDSCs from metastatic
tumor-bearing mice nor overexpression of IL-6 was
Figure 2 Induction of recruitment and reconstitution of MDSCs in non-metastasizing EMT6 cell-bearing mice enhanced cancer cell
metastasis. (A-C) EMT6_Con and EMT6_IL-6 cells were injected into the mammary fat pads of BALB/c mice. MDSCs were analyzed at 21 days.
(A) Percentages of MDSCs at 21 days (n = 6). (B) Primary tumor growth (n = 7). (C) Numbers of metastatic nodules in the lungs at 26 days
(n = 7) and lung sections at 26 days (H & E). (D) EMT6 cells were injected into the mammary fat pads. Three days later, mice were intravenously
injected with splenic MDSCs (5×106/mouse) from 4T1 cell-bearing mice, a total of nine times. Primary tumor growth (n = 5) and representative
photographs of lungs at 26 days. MDSCs, myeloid-derived suppressor cells.
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sufficient to confer on non-metastasizing EMT6 cancer
cells a metastasizing capacity comparable to that of 4T1
breast cancer cells. We assume that metastasizing cancer
cells produce additional effects to potentiate the
recruited MDSCs, thereby leading to distant metastasis.
Metastasizing, but not non-metastasizing, breast cancer
cells activated MDSCs
To evaluate whether metastasizing, but not non-metas-
tasizing, cancer cells further activate recruited MDSCs,
we collected splenic MDSCs from naïve and tumor-
bearing mice and co-cultivated them with 4T1 and
EMT6 cells. Splenic MDSCs co-cultured with 4T1 cells
showed increased production of IL-6, irrespective of
their source (naïve, EMT6 cell-bearing, or 4T1 cell-bearing
mice), compared to those co-cultured with EMT6
cells (Figure 3A). 4T1 cells co-cultured with splenic
MDSCs provided activated signals either in the same
chamber (lower) or a different chamber (upper) in a
Transwell culture assay (Figure 3B), implying that contact-
independent factors were important for activation of
splenic MDSCs. To confirm the critical role of soluble
factors derived from metastasizing breast cancer cells,
conditioned media (CM) from breast cancer cells (4T1-
CM and EMT6-CM) were applied to splenic MDSC
cultures. 4T1-CM, but not EMT6-CM, enhanced the
production of IL-6 by splenic MDSCs (Figure 3C). 4T1-
CM increased IL-6 transcription in splenic MDSCs from
both 4T1cell- and EMT6 cell-bearing mice; EMT6-CM
and recombinant IL-6 only slightly induced the transcrip-
tion of IL-6 [see Additional file 1 Figure S4]. Exposure of
splenic MDSCs to 4T1-CM induced the activation of
several signaling pathways, including Stat3, NF-B, JNK,
ERK and p38 pathways [see Additional file 1, Figure S5].
Using inhibitors of each pathway, we found that the
NF-B, JNK, and p38 signaling pathways were important
in the production of IL-6 by activated MDSCs (Figure
3D). Importantly, confocal microscopic analysis of tissues
Figure 3 Metastasizing cancer cell-derived factors induced excessive IL-6 production by MDSCs. (A) Splenic MDSCs (4×105) were co-
cultured with 4T1 cells (1×104) or EMT6 cells (1×104) for 48 hours. IL-6 levels in the culture supernatants were measured by ELISA. (B-C) Splenic
MDSCs from 4T1 cell-bearing mice were co-cultured with 4T1 cells in Transwell systems (B) or exposed to conditioned media (CM) for 24 hours
(C). (D) Splenic MDSCs were cultured with 4T1-CM in the presence of signaling inhibitors for 24 hours. (E) Immunofluorescence staining of Gr-1
(red), IL-6 (green), and DAPI (blue) in the spleen, tumors and lungs of 4T1 cell-bearing mice. Scale bar = 30 μm (original magnification, ×1,000).
MDSCs, myeloid-derived suppressor cells.
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from 4T1 cell-bearing mice revealed that MDSCs inside
the primary tumor and lung strongly expressed IL-6 while
those in spleen tissues from the same mice expressed
little IL-6, but MDSCs in the primary tumor site of
EMT6-bearing mice did not show increased expression of
IL-6 (Figure 3E and see Additional file 1, Figure S6). In
summary, metastasizing, but not non-metastasizing,
tumor-derived factors induced MDSCs to produce more
IL-6, and full activation of recruited MDSCs occurred
in the primary tumor site and metastatic organs in the
vicinity of metastasizing cancer cells.
Activated MDSCs confer invasive potential on breast
cancer cells and stimulate distant metastasis through
IL-6 trans-signaling
We next evaluated whether activated MDSCs in the
metastasizing tumor microenvironment affect breast
cancer cell behavior. We cultured 4T1 and EMT6 cells
in CM from splenic MDSCs cultivated in the presence
of 4T1-CM or EMT6-CM (4T1/MDSC-CM and EMT6/
MDSC-CM, respectively) (Figure 4A). 4T1 cells cultured
with splenic MDSC-CM showed mild phosphorylation
of Stat3. Moreover, 4T1 cells cultured with 4T1/MDSC-
CM, but not EMT6/MDSC-CM, showed greatly increased
Stat3 phosphorylation within 10 minutes (Figure 4B).
Stat3 phosphorylation levels were increased for 48 hours
in 4T1 cells cultured in the presence of 4T1/MDSC-CM
(Figure 4C and our unpublished data). Unlike 4T1/
MDSC-CM, however, 4T1-CM did not induce the persis-
tent activation of STAT3 [see Additional file 1, Figure S7].
Similar results were obtained for 4T1 cells co-cultured
with splenic MDSCs, but not for 4T1 cells cultured in
the presence of recombinant IL-6 (Figure 4D). These
data suggest that IL-6 was important in inducing Stat3
Figure 4 Stimulation of MDSCs with metastasizing 4T1 cell-derived factors induced persistent Stat3 phosphorylation in cancer cells.
(A) Splenic MDSCs from 4T1 cell-bearing mice were cultivated in the presence of 4T1-CM or EMT6-CM. The conditioned media (MDSC-CM, 4T1/
MDSC-CM, EMT6/MDSC-CM) were harvested and applied to 4T1 and EMT6 cancer cells. (B-C) Phospho-Stat3 and Stat3 levels in 4T1 cells
exposed to each CM for 10 minutes (B) and for the indicated periods of time (C). (D) 4T1 cells (1×104) were co-cultured with splenic MDSCs
(4×105) from 4T1 cell-bearing mice or recombinant mouse IL-6 (1 ng/ml). Phospho-Stat3 and Stat3 levels in 4T1 cells were determined by
Western blotting after the removal of MDSCs. CM, conditioned media; MDSCs, myeloid-derived suppressor cells.
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phosphorylation in 4T1 cells, but that factors other than
IL-6 from tumor-infiltrating MDSCs were needed for
persistent Stat3 phosphorylation.
The recent characterization of IL-6 trans-signaling
[24] suggests that tumor microenvironments may pro-
vide soluble IL-6Ra as well as IL-6 to maximally induce
cancer cell aggressiveness through highly augmented
IL-6 signaling, which is implicated in tumor cell survival,
cancer stem cell characteristics and EMT phenotypes
important for successful distant metastasis of cancer
cells [5,6]. To investigate which cells in the tumor
microenvironment provide soluble IL-6Ra, we measured
levels of soluble IL-6Ra secreted from ex vivo-cultured
splenic MDSCs from naïve, EMT6 cell-bearing, and 4T1
cell-bearing mice and 4T1 cancer cells. MDSCs from
tumor-bearing mice generated more soluble IL-6Ra
compared to 4T1 cells. Compared to those from naïve
and EMT6 cell-bearing mice, splenic MDSCs from 4T1
cell-bearing mice produced more soluble IL-6Ra in
ex vivo culture (Figure 5A and see Additional file 1,
Figure S8). In contrast, splenic MDSCs from naïve,
EMT6 cell-bearing and 4T1 cell-bearing mice expressed
similar levels of surface IL-6Ra chain (Figure 5B).
Production of soluble IL-6Ra involves cell surface-
associated proteases. Adam family proteases, especially
Adam10 and Adam17, have been implicated in IL-6
trans-signaling [25,26]. Non-stimulated splenic MDSCs
from 4T1 cell-bearing mice expressed increased levels of
Figure 5 Increased shedding of sIL-6Ra by the MDSCs of tumor-bearing mice. (A) Soluble IL-6Ra levels in culture supernatants of splenic
MDSCs were measured by ELISA and (B) surface IL-6Ra levels on splenic MDSCs were measured by FACS. (C) The mRNA expression of Adam10
and Adam17 in splenic MDSCs of naïve and tumor-bearing mice were determined by qRT-PCR. (D-E) Protease inhibitor cocktails were applied to
cultures of splenic MDSCs from 4T1 cell-bearing mice for 6 or 24 hours. (D) Membrane-bound IL-6Ra was detected by FACS and (E) soluble
IL-6Ra levels were measured by ELISA. (F) Tissue sections were stained for Adam17 (green), Gr-1 (red), and DAPI (blue) to compare their
localizations. Scale bar = 30 μm (original magnification, ×1,000). FACS, fluorescence-activated cell sorting; MDSCs, myeloid-derived suppressor cells.
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both Adam10 and Adam17 compared to MDSCs from
EMT6 cell-bearing mice and naïve mice (Figure 5C).
When we cultivated splenic MDSCs from 4T1 cell-bearing
mice in the presence of protease inhibitors, levels of the
membrane-bound form of IL-6Ra increased and those of
soluble IL-6Ra levels decreased (Figure 5D and 5E). To
further evaluate the critical role of ADAM family proteases
in IL-6Ra shedding, we also utilized a more specific
protease inhibitor, TAPI-2, an inhibitor of ADAM family
proteases including ADAM17. TAPI-2, as well as a broad-
spectrum protease inhibitors cocktail, decreased shedding
of surface IL-6Ra. [see Additional file 1, Figure S9]. To
confirm the expression of Adam17 and IL-6Ra by MDSCs
in vivo, we analyzed spleen tissues, primary tumor masses
and metastatic lesions in the lungs from 4T1 cell-bearing
mice. Confocal microscopy showed that MDSCs in the
spleen, primary tumor sites and lung expressed increased
levels of Adam17 and IL-6Ra on their surfaces in 4T1
cell-bearing mice compared to those in EMT6 cell-bearing
mice (Figure 5F and see Additional file 1, Figure S10).
Thus MDSCs that were expanded and recruited in the
metastasizing tumor-bearing mice were already capable of
soluble IL-6Ra production, even in the spleen, a site
remote from the metastasizing cancer cells. Taken
together with the increased IL-6 levels only in the vicinity
of metastasizing tumor cells, these findings suggest that
IL-6 trans-signaling occurs preferentially in primary tumor
sites and the metastatic lung but not in the spleen.
To evaluate whether IL-6 trans-signaling is important
for activation of 4T1 breast cancer cells, we cultivated
4T1 cells in the presence of IL-6 and/or soluble IL-6Ra
and evaluated the individual and combined effects of a
blocking anti-IL-6R antibody (which blocks both con-
ventional IL-6 signaling and IL-6 trans-signaling) and a
gp130-Fc fusion protein (which only blocks IL-6 trans-
signaling). When applied individually, IL-6, but not solu-
ble IL-6Ra, increased Stat3 phosphorylation in 4T1
cells. Treatment with both IL-6 and soluble IL-6Ra
further increased the phosphorylation of Stat3, implying
that IL-6 trans-signaling functioned in 4T1 cell activa-
tion (Figure 6A). Inhibition of IL-6 trans-signaling with
gp130-Fc blocked Stat3 phosphorylation as efficiently as
the IL-6R antibody (Figure 6A). To further confirm the
role of IL-6 trans-signaling in the interaction of breast
cancer cells and MDSCs, 4T1 cells were cultured in the
presence of 4T1/MDSC-CM. gp130-Fc fusion protein
treatment inhibited Stat3 phosphorylation in 4T1 cells
to an extent comparable to IL-6R antibody treatment
(Figure 6B). The enhanced IL-6 signaling mediated by
the cancer cell-MDSC interaction augmented 4T1 breast
cancer cell aggressiveness. 4T1 cells cultivated with
4T1/MDSC-CM showed exaggerated invasiveness in a
Matrigel invasion assay, a response that was blocked by
gp130-Fc treatment (Figure 6C). To investigate the role
of IL-6 trans-signaling in in vivo metastasis, we admi-
nistered gp130-Fc to the tumor-bearing mice. Conti-
nuous infusion of gp130-Fc (5 or 10 μg/ea/14 days),
starting from the day following cancer cell injection,
reduced primary tumor growth in the mammary fat pads
(Figure 6D) and lung metastasis in a dose-dependent man-
ner (Figure 6E). These findings support the critical role of
IL-6 trans-signaling in breast cancer cell invasiveness and
metastasis in vivo. As increased IL-6 trans-signaling in
4T1 cell-bearing mice was suggested to occur in the
primary tumor sites and metastatic lung (Figure 3E), we
evaluated whether increased IL-6 trans-signaling in
the lung also affected the efferent phase of cancer cell
metastasis. Treatment with gp130-Fc (2.5 μg/bolus, i.v.)
on day 4 after intravenous cancer cell injection decreased
the lung metastasis of 4T1 cancer cells compared to
vehicle-treated controls (Figure 6F).
Finally, to confirm whether the strong and persistent
Stat3 phosphorylation in MDSC-potentiated cancer cells
is crucial to spontaneous tumor metastasis, we generated
Stat3-knockdown 4T1 (4T1_shStat3) cells [see Additional
file 1, Figure S11]. 4T1_shSTAT3 cells revealed similar
levels of IL-6 production and MDSC recruitments com-
pared to 4T1_Con cells (data not shown). Greatly
increased invasiveness in a Matrigel invasion assay was
observed in control 4T1 (4T1_Con) cells, but not in
4T1_shStat3 cells, after treatment with 4T1/MDSC-CM,
although reduced Stat3 expression itself had no effect on
cancer cell invasiveness (Figure 7A and 7B). Primary
tumor growth in the mammary fat pads was reduced in
4T1_shStat3 cell-bearing mice compared to 4T1_Con
cell-bearing mice, while the reduction in distant lung
metastasis was more dramatic in 4T1_shStat3 cell-bearing
mice which exhibited few metastases (Figure 7C and 7D).
Discussion
In this study, we showed that IL-6 derived from metas-
tasizing murine breast cancer cells recruited MDSCs
and tumor-expanded MDSCs expressed Adam-family
proteases, which facilitated shedding of IL-6 receptors,
thereby providing sIL-6Ra. In addition, factors other
than IL-6, released from the cancer cells, promoted IL-6
production from recruited MDSCs in the vicinity of
cancer cells. MDSC-derived IL-6 and sIL-6Ra induced
persistent activation of STAT3 and increased invasive-
ness of breast cancer cells via an IL-6 trans-signaling
mechanism. This IL-6 trans-signaling also increased
distant metastasis in vivo. From these experiments, we
provide novel information regarding potential tumor-
MDSC synergistic axis involving IL-6 and soluble
IL-6Ra [see Additional file 1, Figure S12].
MDSCs have been suggested to constitute tumor-
favoring microenvironments largely through their sup-
pressive effects on innate and adaptive immunity and
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Figure 6 Activated MDSCs contributed to tumor invasiveness through IL-6 trans-signaling. (A-B) 4T1 cells were treated with recombinant
IL-6 plus soluble IL-6Ra (A) or 4T1/MDSC-CM (B) for 30 minutes in the presence of anti-IL-6R blocking antibody or gp130-Fc. (C) 4T1 cells were
allowed to invade through Matrigel for 18 hours in the presence or absence of 4T1/MDSC-CM and/or gp130-Fc (crystal violet). (D-E) 4T1 cells
were injected into the mammary fat pads. Some mice underwent continuous administration using osmotic mini-pumps (5 or 10 μg for 14 days).
(D) Primary tumor growth and (E) numbers of metastatic masses in the lungs at 26 days. (F) 4T1 cells were injected intravenously into BALB/c
mice (n = 5 mice per group). Some mice received gp130-Fc (2.5 μg) 4 days after cancer cell injection. Numbers of metastatic masses in the
lungs at day 12 were determined. Values are the means ± SEM of each group. *P < 0.05, **P < 0.01, ***P < 0.001. CM, conditioned media; MDSC,
myeloid-derived suppressor cells.
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promotion of angiogenesis [8,9,13,14]. In our murine
breast cancer cell model, 4T1 breast cancer cells
recruited more MDSCs and metastasized more strongly
compared to EMT6 cells, not only in syngeneic immu-
nocompetent BALB/c mice, but also in immunodeficient
NOG mice, in which T, B, and NK cells are defective
(our unpublished data and [27]). This implies that
MDSCs in 4T1 cell-bearing mice induced spontaneous
distant metastasis of cancer cells independently of their
suppressive effects on adaptive and natural-killer cell
anti-tumor immunity. Thus, in this study, we provide
evidence that MDSCs potentiated by metastasizing
breast cancer cells directly enhance the aggressiveness of
cancer cells though trans-signaling by upregulating both
IL-6 and sIL-6Ra secretion in primary tumor sites and
the metastatic lung.
Induced expression of IL-6 in EMT6 cancer cells
caused recruitment of MDSCs in lymphoid organs,
metastatic target organs and primary tumor sites com-
parable to that caused by metastasizing 4T1 cancer cells,
which implies that IL-6 or downstream signaling may be
involved in this process. However, recruitment of
Figure 7 Stat3 phosphorylation in MDSC-activated cancer cells contributed to tumor invasiveness and distant lung metastasis. (A-B)
4T1_Con and 4T1_shStat3 cells were allowed to invade through Matrigel for 18 hours in the presence or absence of 4T1/MDSC-CM. (A) Invaded
4T1 cells (crystal violet). (B) Invaded cells were counted using ImageJ software. (C-D) 4T1_Con and 4T1_shStat3 cells were injected into the
mammary fat pads. (C) Primary tumor growth. (D) Numbers of metastatic masses in the lungs at 26 days. Values are the means ± SEM of each
group (n = 5). CM, conditioned media; MDSC, myeloid-derived suppressor cells.
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MDSCs per se was not enough to guarantee that non-
metastasizing breast cancer cells fully adopted metastatic
capability. Transfer of splenic MDSCs from metastasiz-
ing 4T1 cell-bearing mice increased distant metastasis of
non-metastasizing EMT6 cells but did not imbue them
with the full metastatic capability of 4T1 cells. Based on
the above findings, we assume that additional factors
from metastasizing breast cancer cells affected the hom-
ing of MDSCs into the tumor sites and increased the
potency of recruited MDSCs [18,19,28,29]. Our in vitro
co-culture experiments showed that recruited MDSCs in
the spleens of tumor-bearing mice required additional
activation in the vicinity of metastasizing cancer cells,
predominantly through contact-independent mechanisms.
The outcome of activation of MDSC by metastasizing
cancer cells in vitro can be summarized as exaggerated
augmentation of IL-6 production by MDSCs [18,19].
Immunofluorescence microscopy of different tissues from
4T1 cell-bearing mice indeed showed that MDSCs in
the primary tumor mass and metastatic lung, but not in
the spleen, expressed high levels of IL-6. These findings
suggest that recruited MDSCs may have different roles or
function through different mechanisms depending on the
recruited sites (lymphoid organs versus tumor sites,
primary or metastatic) [30,31].
In contrast to the requirement for contact with metas-
tasizing cancer cells for increased IL-6 production by
MDSCs, the components necessary for increased soluble
IL-6Ra production were increased in MDSCs in the
remote sites of metastasizing tumor-bearing mice, but
not those of non-metastasizing tumor-bearing mice.
Expression levels of both IL-6Ra and the enzymes
responsible for digesting the membrane form into soluble
forms (Adam10 and Adam17) [25,26,32,33] were
increased in the splenic MDSCs of 4T1 cell-bearing
mice. Moreover, simple cultivation of splenic MDSCs
from 4T1 cell-bearing mice increased the expression of
soluble IL-6Ra compared to EMT6 cell-bearing mice.
Thus, at least four remote signals were secreted by
metastasizing 4T1 cancer cells; these induced (1) recruit-
ment of MDSCs to various sites of tumor-bearing hosts,
(2) increased expression of IL-6Ra, (3) increased expres-
sion of Adam family proteases, and (4) highly increased
expression of IL-6 by MDSCs [34,35,18,19,29]. Further
studies are needed to clarify the critical roles of the various
mediators that may be involved in MDSC modulation.
In this study, we convincingly demonstrated that 4T1 cells
responded to IL-6 trans-signaling by MDSCs. However,
as we did not perform experiments specifically inhibi-
ting expression of IL-6 and sIL-6Ra in MDSCs in vivo,
we cannot absolutely rule out the possibilities that IL-6
and sIL-6Ra responsible for metastasis could poten-
tially be coming from other cell types in vivo either the
tumor cells themselves or other cells within the tumor
microenvironment. Further studies are needed to clarify
this aspect.
The importance of IL-6 signaling in promoting tumori-
genesis is well-documented, particularly for tumors asso-
ciated with chronic inflammation such as colitis-associated
colon cancer, pancreatic cancer and hepatocellular carci-
noma [36-39]. In addition to these tumors, increased IL-6
signaling is preferentially found in basal-like breast cancers
and high-grade tumors and is associated with a poor
response to chemotherapy, increased distant metastasis in
xenograft animal models and decreased metastasis-free
survival in patients [5,6]. Thus, IL-6 signaling has been
linked to tumor aggressiveness, including cancer stem cell
phenotypes [5,6,40,41] and EMT phenotypes [42], drug
resistance [43], and anoikis resistance, that is, contact-
independent survival, which is required for travel through
the vascular system [44]. In addition to tumor-derived
IL-6 autocrine signaling [5,6], paracrine IL-6 signaling
within tumor microenvironments has been highlighted
recently. Mesenchymal stem cells constitute the cancer
stem cell niche by providing IL-6 and CXCL7 [45,46].
Paracrine IL-6 signaling from tumor-infiltrating inflamma-
tory cells is more important because these cells have a
greater inflammatory cytokine secretion capacity, includ-
ing IL-6 [47-49]. The caveat for this paracrine signaling is
that cancer cells should express sufficient receptor machi-
neries to recognize the increased IL-6 supply from the
microenvironments. In this way, aggressive breast cancer
cells exploited a trans-signaling mechanism by inducing
the expression of molecules responsible for production of
soluble IL-6 receptors (Adam proteases) from the
recruited inflammatory cells [50]. In terms of STAT3
signaling as a downstream of IL-6, previous reports sug-
gested that knocking down STAT3 using the shRNA tech-
nique in 4T1 cells leads to decreased invasiveness of the
cells in vitro [51]. The differences between this report and
our current study may lie in the perfectness of STAT3
knockdown considering the total absence of phosphory-
lated STAT3 in the previous report compared to our
current study (our unpublished data).
The site of MDSC function in the metastatic tumor-
bearing mice requires further comment. In terms of
sites of MDSC immunosuppressive activity, the available
data are contradictory. Some authors suggest that lym-
phoid organs, including the liver, are the primary sites
of MDSC accumulation and immunosuppression
[30,52], while others emphasized effector sites, such as
inflammatory sites and tumors, but not lymphoid
organs, such as the spleen [31,53,29]. In terms of MDSC
function during the efferent phase of tumor metastasis
and related angiogenesis, accumulation of MDSCs in the
lung, a metastatic target organ, supported the effective
engraftment of metastatic tumor cells at this site
[15,19,54]. Because the metastasis-promoting effects of
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MDSCs in this study occurred in the absence of adaptive
immunity and natural-killer cell activity and there was no
increase in IL-6 signaling in the spleen, MDSCs them-
selves must have directly increased tumor cell metastatic
capability in the tumor sites, either primary tumors or
metastases, but not in the lymphoid organs, affecting
both the afferent and efferent phases of metastasis
through exaggerated IL-6 trans-signaling. Lastly,
although we clearly showed the direct effects of MDSCs
on the in vitro invasiveness and effector phase of lung
metastasis, the co-occurrence of reduction in the primary
tumor size and metastasis in some experiments pre-
vented us to totally rule out the possibilities that differ-
ences in metastasis might be due to differences in tumor
size rather than specific effects of MDSCs on metastatic
capacity.
Conclusions
Our findings reveal that breast cancer cells and MDSCs
form a synergistic mutual feedback loop and that thus-
potentiated MDSCs directly affect breast cancer cell
aggressiveness, leading to spontaneous metastasis. We
have shown that more MDSCs were recruited to the dif-
ferent organs of mice implanted in the mammary fat pads
with high IL-6-producing breast cancer cells and the
depletion of MDSCs by an anti-Gr1 antibody reduced the
numbers of metastatic nodules in the lung. Moreover, it
was shown that when MDSCs were exposed to condi-
tioned media of metastasizing cancer cells, MDSCs
secreted exaggerated IL-6 and soluble IL-6Ra, which
induced persistent activation of STAT3 in cancer cells.
ADAM family proteases responsible for the shedding of
IL-6Ra were also increased on metastasizing cancer-
expanded MDSCs. Furthermore, we confirmed that IL-6
trans-signaling was an important mechanism supported by
tumor-infiltrating MDSCs to drive the metastatic behavior
of cancer cells in vitro and in vivo.
Additional material
Additional file 1: Figure S1. IL-6 levels in culture supernatants of cancer
cells, as determined by ELISA. Figure S2. EMT6 and 4T1 cells were
injected into the mammary fat pads of BALB/c mice. The percentages of
MDSCs (CD11b+Gr-1+) at 19 days were analyzed by flow cytometry (n =
4). Figure S3. (A) IL-6 was overexpressed on EMT6 cells and IL-6 levels in
culture supernatant of selected clone was determined by ELISA. (B)
EMT6_Con and EMT6_IL-6 cells were injected into the mammary fat pads
of BALB/c mice. MDSCs were analyzed at 21 days (n = 6). Figure S4.
Splenic MDSCs from naïve and tumor-bearing mice were treated with
EMT6-CM, 4T1-CM, or recombinant IL-6 (1 ng/ml) for 6 hours. IL-6 mRNA
expression in 4T1-CM-treated splenic MDSCs was detected by RT-PCR.
Figure S5. Splenic MDSCs from 4T1 cell-bearing mice treated with 4T1-
CM for the indicated periods of time. Signaling molecules were detected
by Western blotting. Figure S6. Immunofluorescence staining of Gr-1
(red) and IL-6 (green) in the spleen and tumor of EMT6 cell-bearing mice.
Scale bar = 30 μm (original magnification, ×1,000). Figure S7. 4T1 cells
were treated with 4T1-CM for the indicated periods of time.
Phosphorylated STAT3 were detected by Western blotting. Figure S8.
Soluble IL-6Ra levels in culture supernatants of 4T1 cells were measured
by ELISA. Figure S9. TAPI-2 (100 μM) or Protease inhibitors cocktail (3x)
were applied to cultures of splenic MDSCs from 4T1 cell-bearing mice for
18 hours. (A) Membrane-bound IL-6Ra was detected by FACS and (B)
soluble IL-6Ra levels were measured by ELISA. Figure S10. (A)
Immunofluorescence staining of Gr-1 (red) and IL-6Ra (green) in spleen,
tumor, and lung tissues from 4T1 cell-bearing mice. (B)
Immunofluorescence staining of Gr-1 (red) and IL-6Ra (green) in spleen
from EMT6 cell-bearing mice. (C) Immunofluorescence staining of Gr-1
(red) and Adam17 (green) in spleen from 4T1- and EMT6 cell-bearing
mice. Scale bar = 30 μm. Figure S11. Stat3-knockdown 4T1 cells
(4T1_shSTAT3 cells) generated using the lentiviral vector containing the
short hairpin RNA. STAT3 expression was detected by Western blotting
assay. Figure S12.
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